Todd Wood
DermTech has appointed Todd Wood as chief commercial officer. Wood brings 25 years of pharmaceutical and medical device commercialization experience to the firm. He has previously launched multiple market products, including Juvéderm, Limigan, and Rhofade.
Geoff Smith, Robert Nicol
DNA Script has formed a scientific advisory board, appointing Geoff Smith to serve as chair and Robert Nicol to serve as a second board member.
Smith is an expert in genomic technologies and their applications, having spent more than 10 years working as VP at Solexa/Illumina, where he led the development of many aspects of the core SBS sequencing chemistry, workflows, and platforms, and cell-free DNA pregnancy testing portfolio. After leaving Illumina, Smith served as CEO of Cambridge Epigenetix, and he now works as an advisor to a variety of companies in the genomics space.
Nicol serves as director of the technology labs at the Broad Institute. He is also the cofounder of the MIT-Broad Foundry for Synthetic Biology. Nicol joined the Whitehead Institute/MIT Center for Genome Research in 2001, and directed the sequencing operations and technology development groups at the Broad for more than 12 years.
Jack Crowley, Kavita Patel, Garry Nicholson
Personal Genome Diagnostics has appointed Jack Crowley as its chief financial officer. Crowley most recently served as CFO at Lantheus Medical Imaging, where he led a transition from a private equity-backed to a publicly-traded global life sciences company. Prior to serving as CFO, Crowley also served as Lantheus' chief accounting officer, VP of finance, and global corporate controller. He also served as director of finance and assistant corporate controller at Biogen and director of accounting at Thermo Fisher Scientific.
PGDx has also appointed Kavita Patel and Garry Nicholson to its board of directors. Patel has served in the Obama Administration as director of policy for the Office of Intergovernmental Affairs and Public Engagement in the White House. Prior to the White House, she served as deputy staff director on health on the late Senator Edward Kennedy's staff. She also serves on the board of directors at Dignity Health and SSM Health Care.
Nicholson currently serves as director at Five Prime Therapeutics, G1 Therapeutics, Tmunity Therapeutics, and SQZ Biotechnology. He previously served as president and CEO of XTuit Pharmaceuticals, as well as a member of the firm's board of directors. Prior to that, he served as president of Pfizer Oncology. He has also served on the Pfizer Foundation's board of directors and acted as a member of the firm's Portfolio, Strategy, and Investment Committee. In addition, Nicholson previously held leadership positions in the oncology division of Eli Lilly.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.